AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Coherus Oncology, Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG0063N8V87
1.01▼ 0.04 (-3.81%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
1.05
Day's Range
0.99 – 1.04
52-Week Range
0.94 – 2.62
Volume
641.3K
Avg Volume
1.5M
Share Statistics
Shares Outstanding
Employees
147
Exchange
XNAS
Listed
2014-11-06
Share count as of July 31, 2026

Coherus Oncology, Inc. Common Stock (CHRS) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Coherus Oncology, Inc. Common Stock (CHRS)
What is Coherus Oncology, Inc. Common Stock's Market Cap?
Coherus Oncology, Inc. Common Stock's Market Cap is $156.0M, based on as-reported figures from SEC (XBRL) filings.
What is Coherus Oncology, Inc. Common Stock's Price / Sales?
Coherus Oncology, Inc. Common Stock's Price / Sales is 3.1×, based on as-reported figures from SEC (XBRL) filings.
What is Coherus Oncology, Inc. Common Stock's Revenue (TTM)?
Coherus Oncology, Inc. Common Stock's Revenue (TTM) is $50.9M, based on as-reported figures from SEC (XBRL) filings.
What is Coherus Oncology, Inc. Common Stock's Net Income (TTM)?
Coherus Oncology, Inc. Common Stock's Net Income (TTM) is -$132.1M, based on as-reported figures from SEC (XBRL) filings.
What is Coherus Oncology, Inc. Common Stock's EBITDA?
Coherus Oncology, Inc. Common Stock's EBITDA is -$155.1M, based on as-reported figures from SEC (XBRL) filings.
What is Coherus Oncology, Inc. Common Stock's Diluted EPS (TTM)?
Coherus Oncology, Inc. Common Stock's Diluted EPS (TTM) is -0.86, based on as-reported figures from SEC (XBRL) filings.
What is Coherus Oncology, Inc. Common Stock's EBITDA Margin?
Coherus Oncology, Inc. Common Stock's EBITDA Margin is -304.5%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CHRSAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Net revenue
YoY growth+39.5%+62.0%+64.9%+91.2%
Costs and expenses:
Cost of goods sold
Research and development
Selling, general and administrative
Total costs and expenses
% of revenue326.0%393.7%459.9%483.1%
Loss from operations
% of revenue-226.0%-293.7%-359.9%-383.1%
Interest expense
Other income (expense), net
Loss from continuing operations before income taxes
Net loss from continuing operations
Net income (loss)
% of revenue-144.2%-311.3%-295.3%-307.1%
Net income (loss) per share - Basic (In dollar per share)
Net income (loss) per share - Diluted (In dollar per share)